Companies like INSM are constantly meeting with investors set up by firms like JMP. Believe me when I tell you that of course there are discussions about potential financings and at what levels to make an offering. My guess is that they believe they have enough gas in the tank to do it at higher levels. It would be an easy print at the current levels.
blah blah blah. AAL is having a very stron Q with their domestic & coprporate gains more than offsetting international. The DAL PRASM is just one data point & needs to be examine in totality --- which is fine overall. Q EPS are in solid shape for DAL & they should (as should AAL ) beat wall street estimates. More short-term noise. ALL will be $50+ nicely by year end, If the US (& world economy) keeps showing strength look for a good shot at $55-60+ long out a year on 6.50--7/EPS.
Airlines will begin to report June traffic and update Q2 guidance this week. DAL will report June traffic & updated guidance on Wednesday & Cowen expects them to report at the higher end of June PRASM guidance of up 5-7%. They are looking for AAL to have an excellent quarter as well.
Morgan Stanley raised estimates today, with the 2Q going from $1.87 to $1.95, pushing '14 est from $5.40 to 5.75, raising '15 est from 6.75 to $7, & '16 est to $7.50. Yearend target goes from $46 to $50.
JP Morgan released their 2H'14 Outlook for stocks today. AAL was their top airline pick---as it likely offers investors the greatest upside potential given the company's continued integration progress in the American/US Airways merger & our belief that a formal share buyback could be instituted by yearend.
Are you referring to the insider sales just posted ? That's why the stock is down. They paid $1 so selling at $4 is OK for them.
Please summarize your familiarity with THLD & what it is the company does ---- that would be a helpful start. Once you show where you are on the learning curve I'm sure many will help bring you up to speed/
Ha Ha Dendeon sub $2....another loser. Keep your big mouth shut---apparently you have missed the Biotech Investment Cycle over the last decade ! Keep buying you little lottery tickets little rookie --- hopefully there is some Social Security still available as you sure are gonna need it ! KEEP PREDICTING-----VERY FUNNNEEEEE !
You apparently haven't read the analyst responses today. $30ish+ sounds like a more reasonable target based on potential FDA approval.
The fundamental story has never been brighter !!! Breakthrough therapy designation right around the corner. Look for at least a 50% to $6/share this year !